Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04632953 · ClinicalTrials.gov registry record
Long-Chain Fatty Acid Oxidation Disorders In-Clinic Disease Monitoring Program
A clinical trial of Long-chain Fatty Acid Oxidation Disorders (LC-FAOD), sponsored by Ultragenyx Pharmaceutical.
- Active
- Registry status
- 150
- Enrollment target
- 16
- Study locations
NCT04632953 is a study of Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) that is active but no longer recruiting, run by Ultragenyx Pharmaceutical. The registered enrollment target is 150 participants. The trial reports 16 study locations across 15 states.
The verdict
NCT04632953, a study of Long-chain Fatty Acid Oxidation Disorders (LC-FAOD), is active but no longer recruiting, sponsored by Ultragenyx Pharmaceutical.
- ACTIVE NOT RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 16
- Study locations
Study Summary
The primary objective of this study is to assess the long-term safety, including pregnancy, infant, and lactation outcomes, of patients with LC-FAOD who are enrolled in the DMP.
Conditions Studied
Interventions
- OTHER No Intervention
Study Locations (16)
Ontario
- CHEO (Children's Hospital Eastern Ontario) - Ottawa
- SickKids (The Hospital for Sick Children) - Toronto
Arizona
- Phoenix Children's Hospital - Phoenix
California
- University of California San Francisco - San Francisco
Colorado
- Children's Hospital of Colorado - Aurora
Florida
- University of South Florida - Tampa
Georgia
- The Emory Clinic - Atlanta
Illinois
- Ann & Robert H. Lurie Children's Hospital - Chicago
Massachusetts
- Boston Children's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2021-11-30 |
| Est. Completion | 2035-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04632953
The ClinicalTrials.gov registry entry for NCT04632953 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ultragenyx Pharmaceutical, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) appearing as the primary indexed condition, and to 1 intervention - of which No Intervention is the first listed.
NCT04632953 reports 16 study locations spanning 15 distinct geographic areas - top geographies include Ontario, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT04632953 about?
NCT04632953 is a clinical study titled "Long-Chain Fatty Acid Oxidation Disorders In-Clinic Disease Monitoring Program". The primary objective of this study is to assess the long-term safety, including pregnancy, infant, and lactation outcomes, of patients with LC-FAOD who are enrolled in the DMP.
What is the current status of trial NCT04632953?
This trial is currently active not recruiting. The enrollment target is 150 participants. The study started on 2021-11-30. Estimated completion is 2035-12.
What conditions does trial NCT04632953 study?
This clinical trial studies the following conditions: Long-chain Fatty Acid Oxidation Disorders (LC-FAOD).
What interventions are being tested in trial NCT04632953?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT04632953?
This trial is sponsored by Ultragenyx Pharmaceutical, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04632953 being conducted?
This trial has 16 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.